Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR2554 combinations in advanced gastric/GEJ cancer
NCT07102901Phase 2Recruiting
- Sponsor
- Hengrui
- Start
- Sep 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zeprumetostat in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Hengrui. Started Sep 2025; status: recruiting.
02
Drugs
zeprumetostat
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07102901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07102901.